Systems biology for the functional validation of genetic determinants of skeletal diseases
SME-targeted Collaborative Project (large-scale integrating research project)
HEALTH.2013.2.1.1-1: Functional validation in animal and cellular models of genetic determinants of diseases and ageing processes
The overall concept of this large-scale collaborative project is to functionally validate genetic determinants of common and rare skeletal diseases to gain a mechanistic understanding of disease processes and age-related changes and to deliver new and validated therapeutic targets. SYBIL brings together a complementary translational and transnational group of world-class scientists, systems biologists, disease modellers, information technologists and industrialists that will achieve critical mass to deliver the ambitious objectives of this programme of research.
SYBIL comprises 18 Partners with a budget of 12 million Euros over 5 years.
|1||University of Newcastle upon Tyne (UNEW)||UK|
|2||University of L’Aquila (UNIVAQ)||IT|
|3||University of Manchester (UNIMAN)||UK|
|4||Alacris Theranostics (ALACRiS) – SME||DE|
|5||University of Pavia (UniPav)||IT|
|6||Polygene (PG) – SME||CH|
|7||Institute of Genetic and Biomedical Research (IRGB)||IT|
|8||Institut National de la Santé et de la Recherche Médicale (INSERM)||FR|
|9||Certus Technologies (Certus) – SME||UK|
|10||Charité – Universitaetsmedizin Berlin (Charité)||DE|
|11||GATC Biotech AG (GATC) – SME||DE|
|12||University Medical Center Hambourg Eppendorf (UKE)||DE|
|13||Evercyte (Evercyte) – SME||AU|
|14||University Hospital of Cologne (UKK)||DE|
|15||PRIMM Srl (PRIMM) – SME||IT|
|16||University of Freiburg (UKL-FR)||DE|
|17||University of Antwerp (UA)||BE|
|18||Finovatis (Finovatis) – SME||FR|
More information here.